Loading...
 
Back to the list
Mediterr J Rheumatol 2024;35(Suppl 1):10-9
Article Links
Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis
Styliani Partalidou1, Dimitrios Patoulias2, Kleopatra Deuteraiou3, Paraskevi Avgerou3, George Kitas4, Maria Tzitiridou-Chatzopoulou3, Theodoros Dimitroulas3
Authors Information

11st Department of Internal Medicine, 424 Military Hospital of Thessaloniki, 56429, Thessaloniki, Greece
2Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", 54642 Thessaloniki, Greece

34th Department of Internal Medicine, Hippokration General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54642, Thessaloniki, Greece

4Research & Development, Dudley Group NHS Foundation Trust and University of Birmingham, United Kingdom

Keywords: JAK inhibitors, TNF inhibitors, rheumatoid arthritis, thromboembolic events, cardiovascular events
References
  1. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol 1998 May;27 Suppl 1:S18-24.
  2. Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F, et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmunity Reviews 2021 Feb;20(2):102735. https://doi.org/10.1016/j.autrev.2020.102735.
  3. Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun Rev 2021 Apr;20(4):102776.
  4. Fragoulis GE, Panayotidis I, Nikiphorou, E. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment. Curr Vasc Pharmacol 2020;18(5):431-46.
  5. Mansour R, Azrielant S, Watad A, Tiosano S, Yavne Y, Comaneshter D, et al. Venous thromboembolism events among RA patients. Mediterr J Rheumatol 2019;30:38–43.
  6. Nikiphorou E, De Lusignan S, Mallen CD, Khavandi K, Bedarida G, Buckley CD, et al. Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. Heart 2020;106:1566–72.
  7. Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis 2021;80:169–75.
  8. Zhang Y, Lu N, Peloquin C, Dubreuil M, Neogi T, Aviña-Zubieta JA, et al. Improved survival in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis 2017;76:408–13.
  9. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022;386:316–26.
  10. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017;13:234–43.
  11. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82:3–18.
  12. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ Mar 29:372:n160.
  13. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580–8.
  14. Chapter 10: Analysing data and undertaking meta-analyses | Cochrane Training. https://training.cochrane.org/handbook/current/chapter-10#_Ref180058364.
  15. Risk of bias tools - Current version of ROBINS-I. https://sites.google.com/site/riskofbiastool/welcome/home/current-version-of-robins-i?authuser=0.
  16. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials.
  17. McMaster University > CE&B Grade > About GRADE. https://cebgrade.mcmaster.ca/aboutgrade.html.
  18. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. N Engl J Med 2012;367:508–27.
  19. Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: A phase III randomised clinical trial. Ann Rheum Dis 2021;80:848–58.
  20. Fang YF, Liu JR, Chang SH, Kuo CF, See LC. Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis. Int J Rheum Dis 2022;25:1254–62.
  21. Fleischmann R, Pangan AL, Song I-H, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol 2019;71:1788–800.
  22. Frisell T, Bower H, Morin M, Baecklund E, Di Giuseppe D, Delcoigne B, et al. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann Rheum Dis 2023;82:601–10.
  23. Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M,  Sbidian E. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: A nationwide cohort study. Ann Rheum Dis 2022;82:182–8.
  24. Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of Tofacitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis 2022;81:798–804.
  25. Mok CC, So H, Yim CW, To CH, Lao WN, Wong SPY, et al. Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry. Rheumatology (Oxford) 2023 May 2:kead198. doi:10.1093/rheumatology/kead198.
  26. Salinas CA, Louder A, Polinski J, Zhang TC, Bower H, Phillips S, et al. Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases. Rheumatol Ther 2023;10:201–23.
  27. Wisłowska M. Comparison of treatment of severe rheumatoid arthritis patients with biological  agents and JAK-STAT inhibitors. An observational study. Reumatologia 2022;60:81–91.
  28. Taylor PC, Keystone EC, Van Der Heijde D, Weinblatt ME, Del Carmen Morales L, Gonzaga, J. R, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. NEJM 2017;376:652–62.
  29. Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (United Kingdom) 2022;61:121–30.
  30. Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: A Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis 2022;82:189–97.
  31. Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 2021;80:304–11.
  32. Tong X, Shen CY, Jeon HL, Li Y, Shin JY, Chan SCW, et al. Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: A multi-centre cohort study. J Intern Med 2023;294:314–25.
  33. Uchida T, Iwamoto N, Fukui S, Morimoto S, Aramaki T, Shomura F, et al. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study. Rheumatology 2023 Oct 3;62(10):3358-65.  doi:10.1093/rheumatology/kead079.
  34. Hall S, Nash P, Rischmueller M, Bossingham D, Bird P, Cook N, et al. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. Rheumatol Ther 2018:5:383–401.
  35. Bower H, Frisell T, di Giuseppe D, Delcoigne B, Askling J. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis. RMD Open 2023 Nov 23;9(4):e003630.
  36. Min HK, Kim H, Jeong HJ, Kim SH, Kim H-R, Lee S-H, et al. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data. Epidemiol Health 2023;45:e2023045.
  37. Song Y-K, Lee G, Hwang J, Kim J-W, Kwon J-W. Cardiovascular risk of Janus kinase inhibitors compared with biologic  disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study. Front Pharmacol 2023;14:1165711.
  38. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. NEJM 2012;367:508–19.
  39. Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open 2023 Feb;9(1):e002735.
  40. Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis 2022;81:798–804.
  41. Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford) 2021;61:121–30.
  42. Zhang J, Li W, Gong M, Gu Y, Zhang H, Dong B, et al. Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis. Front Pharmacol 2023 Jun 7;14:1189389.
  43. Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open 2023 Feb;9(1):e002735. doi:10.1136/rmdopen-2022-002735.
  44. Li L, Lu N, Avina-Galindo AM, Zheng Y, Lacaille D, Esdaile JM, et al. The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study. Rheumatology (Oxford) 2021;60:188–95.
  45. Campanaro F, Zaffaroni A, Cacioppo E, Cappelli A, Bertù L, Donadini MP, et al. Venous and arterial thromboembolic risk of Janus kinase inhibitors: a systematic review with meta-analysis. Rheumatology (Oxford) 2023;62:3245–55.
  46. Charles-Schoeman C, DeMasi R, Valdez H, Soma K, Hwang LJ, Boy MG, et al. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis Rheumatol 2019;71:1450–9.
  47. Gouverneur A, Avouac J, Prati C, Cracowski JL, Schaeverbeke T, Pariente A, et al. JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study. Eur J Clin Pharmacol 2022:78:1981–90.
  48. Dong Z, Ye X, Chen C, Wang R, Liu D, Xu X, et al. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration’s Adverse Event Reporting System. Br J Clin Pharmacol 2022;88:4180–90.
  49. Avouac J, Fogel O, Hecquet S, Daien C, Elalamy I, Picard F, et al. Recommendations and metaanalyses Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases. Joint Bone Spine 2023;90:105592.